Status:
UNKNOWN
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
Lead Sponsor:
Fundación Marques de Valdecilla
Collaborating Sponsors:
Instituto de Investigación Marqués de Valdecilla
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Conditions:
Schizophrenia
Psychosis
Eligibility:
All Genders
18-60 years
Brief Summary
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
Detailed Description
Schizophrenia is a severe brain disorder with an excess mortality and reduced life expectancy. It has been proposed that around 60% of this excess mortality is due to physical pathology, mostly cardio...
Eligibility Criteria
Inclusion
- Patients followed in the First Episode Psychosis Clinical Program (PAFIP) from February 2001 to December 2007.
- Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria of brief psychotic disorder, schizophreniform disorder, schizophrenia or schizoaffective disorder.
Exclusion
- Meeting DSM-IV criteria for drug dependence.
- Meeting DSM-IV criteria for mental retardation.
- Having a history of neurological disease or head injury.
Key Trial Info
Start Date :
February 12 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03481465
Start Date
February 12 2018
End Date
December 1 2020
Last Update
December 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Marqués de Valdecilla
Santander, Cantabria, Spain, 39008